(Q44943129)

7 December 2017

title

A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours (English)

1 reference

7 December 2017

C Colosimo

1

1 reference

7 December 2017

M V Knopp

2

1 reference

7 December 2017

X Barreau

3

1 reference

7 December 2017

E Gérardin

4

1 reference

7 December 2017

M A Kirchin

5

1 reference

7 December 2017

F Guézénoc

6

1 reference

7 December 2017

K P Lodemann

7

1 reference

7 December 2017

publication date

15 June 2004

1 reference

7 December 2017

1 reference

7 December 2017

volume

46

1 reference

7 December 2017

issue

8

1 reference

7 December 2017

page(s)

655-665

1 reference

https://scigraph.springernature.com/pub.10.1007/s00234-003-1128-4

7 December 2017

exact match

0 references

cites work

328. Note: The Use of None-Parametric Methods in the Statistical Analysis of the Two-Period Change-Over Design

1 reference

12 December 2020

Gadodiamide injection and gadopentetate dimeglumine. A double-blind study in MR imaging of the CNS

1 reference

12 December 2020

Magnetic resonance imaging of metastatic disease to the brain with gadobenate dimeglumine

1 reference

12 December 2020

Magnetic resonance imaging in patients with central nervous system pathology: a comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (Gd-DTPA).

1 reference

12 December 2020

Immunohistochemical demonstration of serum proteins in human cerebral gliomas

1 reference

12 December 2020

MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol.

1 reference

12 December 2020

Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases

1 reference

12 December 2020

High-dose gadoteridol in MR imaging of intracranial neoplasms.

1 reference

12 December 2020

1 reference

12 December 2020

Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium

1 reference

12 December 2020

Safety and efficacy of dotarem (Gd-DOTA) versus magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system

1 reference

12 December 2020

A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (Gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology.

1 reference

12 December 2020

Gd-enhanced MR imaging of brain metastases: contrast as a function of dose and lesion size

1 reference

12 December 2020

Gadolinium-DOTA enhanced MR imaging of intracranial lesions

1 reference

12 December 2020

A double-blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MRI of the central nervous system

1 reference

12 December 2020

Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain

1 reference

12 December 2020

Triple-dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients

1 reference

12 December 2020

Detection of intracranial metastases: a multicenter, intrapatient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dosage

1 reference

12 December 2020

Assessment of gadobenate dimeglumine for magnetic resonance angiography: phase I studies.

1 reference

12 December 2020

Contrast-enhanced MRI of the central nervous system: Comparison between gadodiamide injection and gadolinium-DTPA

1 reference

12 December 2020

Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging.

1 reference

12 December 2020

Increased detection of intracranial metastases with intravenous Gd-DTPA.

1 reference

12 December 2020

Principles of contrast enhancement in the evaluation of brain diseases: an overview

1 reference

12 December 2020

Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: effect of dose on lesion detection and delineation

1 reference

12 December 2020

Comparison of single- and triple-dose contrast material in the MR screening of brain metastases

1 reference

12 December 2020

Randomised double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA)

1 reference

12 December 2020

Phase III, randomized, double-blind, cross-over comparison of gadoteridol and gadopentetate dimeglumine in magnetic resonance imaging of patients with intracranial lesions

1 reference

12 December 2020

The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis

1 reference

12 December 2020

Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison

1 reference

12 December 2020

Gadodiamide injection as a contrast medium for MRI of the central nervous system: a comparison with gadolinium-DOTA.

1 reference

12 December 2020

Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.

1 reference

12 December 2020

Contrast dosage in the neuroimaging of brain tumors. Principles and indications.

1 reference

12 December 2020

Improved contrast of enhancing brain lesions on postgadolinium, T1-weighted spin-echo images with use of magnetization transfer

1 reference

12 December 2020

Experience with high-dose gadolinium MR imaging in the evaluation of brain metastases

1 reference

12 December 2020

Renal time-resolved MR angiography: quantitative comparison of gadobenate dimeglumine and gadopentetate dimeglumine with different doses

1 reference

12 December 2020

10.1007/S00234-003-1128-4

Identifiers

DOI

1 reference

7 December 2017

1 reference